Danaher Corporation (NYSE:DHR) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 17, Danaher Corporation (NYSE:DHR) announced an agreement to acquire Masimo Corporation (NASDAQ:MASI) for nearly $9.9 billion. In the all-cash deal, Danaher will acquire 100% of the common shares outstanding at $180 per share. This translates into 2027 forecasted EBITDA multiples of 15x and 18x, with and without potential synergies, respectively. All-Cash Masimo Deal Offers Strong Strate ...

Microbot Medical’s recent achievement comes on the heels of its FDA 510(k) clearance for the LIBERTY system, which is designed for precision in peripheral endovascular procedures.The adoption by Tampa General Hospital is seen as a significant endorsement of LIBERTY’s value, with the hospital’s leadership emphasizing the technology’s potential to transform patient care and enhance physician safety.The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution in its category, aimi ...

Core Insights - Becton, Dickinson and Company (BDX) has launched the BD Vacutainer Urine Complete Cup Kit, a three-tube urine collection system aimed at enhancing diagnostic testing capabilities from a single specimen [1][5] - The product is designed to improve laboratory efficiency and safety by maintaining specimen integrity and reducing contamination risks [2][12] Product Features - The kit includes a sterile urine collection cup with an integrated transfer mechanism, a dedicated tube for culture and sensitivity testing, a separate tube for urinalysis, a non-additive discard tube, and a castile wipe for patient preparation [9][10] - Its third-tube design allows for expanded diagnostic testing from a single urine sample, eliminating the need for manual transfers [2][9] Strategic Focus - The launch reflects BD's commitment to advancing collection technologies that enhance diagnostic reliability and improve patient management [3][5] - By addressing preanalytical contamination, the product aims to strengthen BD's position in the urinalysis market and support operational improvements in hospitals and labs [5][11] Market Context - BDX currently has a market capitalization of $52.79 billion [6] - The biological sample collection kits market is projected to reach $11 billion by 2026, with a CAGR of 8.9% through 2035, driven by the demand for accurate diagnostics and advanced technologies [13] Stock Performance - Following the product announcement, BDX shares fell by 0.6%, and the company has seen a 5.3% decline over the past six months, contrasting with a 22.3% growth in the industry and a 9.3% rise in the S&P 500 [4][8]

Management repeatedly emphasized changes to the spine distributor network. Calafiore said Orthofix’s top 30 U.S. distributor partners grew net sales 25% year-over-year in Q4 and 27% on a trailing 12-month basis, which he described as validation of the channel strategy. He also said that as of Q4 2025, more than 75% of U.S. net sales were driven by the top 30 distributor partners, compared with “less than a half” at the start of 2024.Global limb reconstruction: Q4 net sales of $38.0 million , driven by 8% U. ...

Operating trends also improved. The company reported a fourth-quarter net loss from operations of $3.9 million , down 79% from Q4 2024, and adjusted EBITDA of positive $5.5 million , compared with negative $13.1 million in the year-ago quarter. CFO Raj Denhoy (who announced a transition into a strategy role) said the year-over-year adjusted EBITDA improvement of $18.6 million was driven by strong sales and higher U.S. gross profit, alongside tighter expense management.Establishment Labs posted a fourth-quar ...

Hartley said gross profit was negatively impacted by $1.9 million in one-time costs in the fourth quarter associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed margin pressure mainly to higher product costs related to additional testing steps as Avance transitioned to a biologic, partially offset by fewer inventory write-offs and lower shipping costs following the case stock program’s discontinuation.G ...

By Arasu Kannagi Basil Feb 24 (Reuters) - Medtronic's MiniMed Group said on Tuesday it was targeting up to $7.86 billion valuation in its U.S. initial public ‌offering, marking a step forward in the medical device maker's plan to ‌separate its diabetes business. The Northridge, California-based unit, a heavyweight in diabetes care and which makes products such ​as insulin pumps, glucose monitoring systems and sensors, is seeking to raise up to $784 million in its IPO by offering 28 million shares priced ...

Avanos Medical (NYSE:AVNS) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDave Pacitti - CEOJason Pickett - VP of Corporate Finance, Tax, and TreasurerScott Galovan - SVP and CFOConference Call ParticipantsDanny Stauder - Director and Equity Research AnalystOperatorNote that this call is being recorded on February 24th, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.Jason PickettGood morning, ever ...

Avanos Medical (NYSE:AVNS) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDave Pacitti - CEOJason Pickett - VP of Corporate Finance, Tax , and TreasurerScott Galovan - SVP and CFOConference Call ParticipantsDanny Stauder - Director and Equity Research AnalystOperatorNote that this call is being recorded on February 24th, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.Jason PickettGood morning, eve ...

Orthofix Medical (NasdaqGS:OFIX) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsJulie Andrews - CFOJulie Dewey - Chief Investor Relations and Communications OfficerMassimo Calafiore - President and CEOMathew Blackman - Managing DirectorMichaela Smith - Equity Research AssociateTom Stephan - AVPConference Call ParticipantsMike Petusky - Managing Director and Senior Research AnalystOperatorThank you. I would now like to turn the call over to Julie Dewey.Julie DeweyThank you, operator, ...